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Background: Schizophrenia is a chronic mental illness that requires lifelong antipsychotic 
treatment. Therapy discontinuation, often due to poor adherence, increases the risk of relapses 
after both first and subsequent psychotic episodes. Long-acting injectable (LAI) antipsychotic 
drugs (APDs) have been introduced to increase therapeutic adherence, reducing blood-level 
variability compared to corresponding oral preparations.
Purpose: To compare the effectiveness of three LAI-APDs: aripiprazole (Apr) prolonged 
release once monthly (OM) haloperidol decanoate (Hal-D) and paliperidone palmitate 
(PP-OM).
Methods: We retrospectively collected data for all patients with schizophrenia or other 
psychoses (n=217) treated with the three LAI-APDs for the first time from January 1, 2012 
to October 31, 2016: n=48 with Apr-OM, n=55 with Hal-D, and n=114 with PP-OM. After 
6 and 12 months of LAI treatments, we assessed clinical and functioning improvement, urgent 
consultations, psychiatric hospitalizations, adverse effects, and dropout. We compared urgent 
consultations and psychiatric hospitalizations required by the same patient 6 and 12 months 
before and after LAI implementation. Data were statistically analyzed.
Results: The three LAI groups differed significantly only for “need for economic support from 
social service” (more frequent in the Hal-D group) and “schizoaffective disorder” (prevalent 
in the Apr-OM group). Apr-OM was prescribed at the maximum dose required by the official 
guidelines, whereas the other two LAIs were prescribed at lower doses. After 6 and 12 months’ 
treatment with the three LAI-APDs, we registered similar and significant reductions in both 
urgent consultations and psychiatric hospitalizations (P,0.001) and overlapping clinical and 
functioning improvement-scale scores (P,0.001), and 14.28% of patients dropped out, with 
no difference among the three LAI-APDs. Different kinds of adverse effects, though similar 
for number and severity, were reported in the three LAI groups.
Conclusion: Our results suggest that both first- and second-generation LAI-APDs represent 
important therapeutic options, useful for improving schizophrenia’s clinical course and its 
economic burden. Our study, which offers a wide and comprehensive observation of real-world 
clinical settings, combined an effectiveness evaluation through mirror analysis performed for 
each individual patient to a subsequent comparison among the three LAI-APDs, allowing us a 
more complete evaluation of clinical efficacy.
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Introduction
Schizophrenia has a prevalence of 0.3%–0.7%,1 and is 
considered the 14th leading cause of disability by the World 
Health Organization.2 Schizophrenia is a chronic mental 
illness that requires lifelong treatment. Antipsychotic drugs 
(APDs) form the cornerstone of treatment for schizophrenia, 
and APD discontinuation, often due to poor adherence, 
increases the risk of relapses after both first and subsequent 
psychotic episodes.3 The risk of relapse is estimated at 77% 
in the first year and up to 90% in the following 2 years, but 
it is around 3% in patients who continue to take drugs.4 
Protocols of incontinuous intake of APDs are associated 
with triple the risk of relapse compared to continuous 
maintenance therapy.5 Another study estimated an increase 
of double to sixfold in relapse risk in schizophrenia without 
drug therapy.6 A wide meta-analysis7 compared patients on 
long-term maintenance APD therapy with those who were 
treated only during symptomatic exacerbations in an incon-
tinuous way: subjects who continued long-term maintenance 
APD therapy showed fewer relapses and hospitalizations 
than those who received intermittent therapy without signifi-
cant differences in terms of side effects. The CATIE study 
on the efficacy of therapeutic interventions for schizophrenic 
pathology showed a rate of interruption of APD therapy at 
18 months of 64%–82%, without differences between typical 
and atypical APDs.8 Several factors contribute to nonadher-
ence, such as depressive symptoms, cognitive impairment, 
inadequate therapeutic projects, substance abuse, labile 
family support, and poor therapeutic alliance.9 APD treat-
ment is also effective for cognitive functions, fostering an 
important benefit in patients taking drugs continuously after 
a first psychotic episode, without substantial differences 
between typical or atypical APDs.10–12 In this regard, long-
acting injectable (LAI) APDs may be particularly indicated 
in young subjects, due to their effectiveness in preventing 
cognitive deficits13 and playing a long-term protective role 
against the loss of cerebral gray matter, in particular in the 
frontal lobe.14
LAI-APDs have been introduced to increase therapeutic 
adherence, reducing blood-level variability compared to 
corresponding oral preparations.15 The first LAI-APD, flu-
phenazine decanoate, was put on the market in 1966 in the 
historical context of large-scale deinstitutionalization and a 
consequent need for effective community treatments.15 Over 
the years, other LAI-APDs were developed from the so-called 
first-generation APDs (FGAs) through esterification of the 
molecules with medium–long-chain saturated fatty acids to 
favor the slow release of the active ingredient by hydrolysis. 
In more recent years, new LAI-APDs were synthesized with 
second-generation APDs (SGAs).
The National Institute for Health and Care Excellence 
guidelines (2014)16 and the main American and Australian 
guidelines17–19 recommend the use of LAI treatment in 
patients nonadherent to therapies with recurrent relapses or 
if the patient requests treatment with an LAI-APD after a 
first psychotic episode. LAIs do not differ significantly in 
safety and tolerability from their corresponding oral drugs, 
as evidenced by two recent meta-analyses,20,21 which detected 
similar dropout percentages due to side effects and observed 
similar incidence of serious adverse events in both oral and 
LAI treatments.
Numerous randomized controlled trials (RCTs) compar-
ing oral APDs with long-acting formulations have reported 
conflicting results,6,22 probably due to the study methodol-
ogy. In accordance with Kane et al,23 the use of prospective 
RCTs to investigate the efficacy of LAI-APDs in preventing 
relapses presents several problems, among which is selection 
bias due to the enrolment of patients with different therapy 
adherence from real-world settings. Another problem with 
RCTs can be represented by the so-called Hawthorne effect, 
which indicates the possible reactive behavior of patients in 
clinical research due to their awareness of being observed.13 
Otherwise, studies with mirror-type designs that compared 
between specular periods of oral APD and LAI treatments 
in the same patient or retrospective studies collecting data 
from national or international registers or cohort studies con-
ducted in clinical settings have confirmed LAI-APD efficacy 
in improving schizophrenia’s clinical course.24–30 However, 
studies with a mirror design can be burdened with an “expec-
tation bias”, since they usually evaluate the transition from 
oral APDs to LAIs and not the other way around, and can also 
be influenced by organizational and cultural factors related 
to psychiatric services, which change over time.28
haloperidol decanoate
Haloperidol decanoate (Hal-D) is the long-acting formulation 
of the typical Hal APD, used in clinical practice for many 
years and approved in Italy since the 1980s.31 Some authors 
have found that a dose of 200 mg once a month (OM) is 
associated with minor symptomatic exacerbations, with no 
differences in side effects or subjective well-being of the 
patient.32 A double-blind, randomized trial showed that doses 
higher than 25 mg OM were equally effective in preventing 
relapse.33 Hal-D has been shown to be effective in numer-
ous studies, with no significant differences compared to oral 
Hal34 or other LAIs.35
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Paliperidone palmitate
In 2009, paliperidone palmitate (PP), palmitate ester, and 
the long-acting form of the APD paliperidone (9-hydroxy-
risperidone), the main metabolite of risperidone, were put on 
the market. In Europe and Italy, PP-OM has been approved 
for maintenance therapy of schizophrenia in adults previ-
ously stabilized with risperidone or paliperidone per os.36 
More recently, a new formulation of PP administered every 
3 months has become available for the same indications of 
PP-OM.37 The efficacy of PP has been supported by many 
studies, such as the PALMFlexS multicenter, open-label, 
flexible-dose trial, which explored tolerability, safety, and 
treatment response in three arms of acute and nonacute but 
symptomatic adult patients previously unsuccessfully treated 
with LAIs or oral APDs.38–40 The effectiveness of PP-OM in 
comparison with previous APD treatments has been shown in 
terms of quality of life from a recovery-oriented perspective.41 
PP-OM has also shown low rates of dropout in naturalistic 
cohort studies, with an acceptably safe metabolic impact.42–44
aripiprazole prolonged release
Aripiprazole (Apr) prolonged release OM at 300 mg and 
400 mg has been approved and marketed in Italy and Europe 
for maintenance treatment of schizophrenia in adult patients 
previously stabilized with oral Apr.45 Apr prolonged release is 
superior to placebo46 and not inferior to its oral formulation.46 
Numerous studies have also highlighted its tolerability and 
efficacy as maintenance therapy for adult schizophrenic 
patients, with a low impact on weight and hematic levels 
of glucose and lipids.47–49 Apr shows fewer metabolic side 
effects and a reduced incidence of hyperprolactinemia com-
pared to other atypical APDs.50,51
Comparison of LAI efficacy
Several studies have shown the noninferiority of PP-OM 
compared to prolonged-release risperidone in efficacy and 
incidence of side effects, both in Caucasian populations and 
other ethnic groups.52,53 A meta-analysis showed less use of 
anticholinergics in patients treated with PP in comparison 
with those treated with prolonged-release risperidone.54
One study showed that the switch from Hal-D or fluphen-
azine decanoate to risperidone prolonged release produced 
more frequent treatment interruptions and side effects 
(weight gain and hyperprolactinemia), with no difference 
in clinical efficacy.55 A comparative study of prolonged-
release risperidone and first-generation LAI-APDs (fluphen-
azine and Hal-D) did not show any differences in terms of 
treatment interruption, hospitalizations, or associated oral 
APDs; however, patients treated with neuroleptic depot 
complained of major extrapyramidal symptoms and thus 
more frequently took anticholinergics.56 A similar study,57 
which compared 1-year treatments of prolonged-release 
risperidone, flupentixol, and Hal-D, highlighted that Hal-D 
was more effective in preventing relapse and prolonged-
release risperidone induced lower extrapyramidal symptom 
incidence but greater use of psychiatric services compared 
to the other two LAI-APDs.
A double-blind RCT comparing Hal-D and PP58 showed 
overlapping efficacy for the two drugs, but significant dif-
ferences in terms of side effects, as paliperidone induced 
greater weight gain and hyperprolactinemia, while Hal 
more frequently caused extrapyramidal symptoms and 
consequently greater use of anticholinergics. An 18-month 
retrospective study59 comparing 238 patients on prolonged-
release risperidone (n=102), PP (n=31), or zuclopenthixol 
decanoate (n=105) reported a greater interruption rate, due to 
both general causes and inefficacy, as well as more frequent 
occurrence of psychiatric hospitalizations in patients treated 
with PP in comparison to the other two LAIs.
Some studies60,61 comparing PP with prolonged-release 
Apr have concluded that Apr-OM is superior in clinical 
improvement, quality of life, and discontinuation of therapy. 
Other research has confirmed the advantage of Apr-OM 
in pharmacoeconomic terms.62 On the contrary, other 
studies2,63,64 have highlighted the superior pharmacological 
efficacy of PP compared to the other LAI-SGAs, associated 
with lower economic cost per patient, better quality of life, 
lower rate of relapse, and fewer treatment interruptions.
Pharmacoeconomic comparison has shown that patients 
treated with PP-OM presented a reduction in psychiatric 
hospitalizations and urgent consultations compared to those 
treated with risperidone prolonged release, resulting in sig-
nificantly lower monthly expense per patient.65 This result 
was also confirmed by other authors, who underlined the 
economic convenience of PP-OM compared to risperidone 
prolonged release in terms of minimization of costs with 
similar efficacy and tolerability.66 Currently, there are no 
unequivocal indications of superior efficacy of one LAI 
compared to another, as pointed out by a recent study.67
The purpose of this study was to compare the effective-
ness of Hal-D, PP-OM, and prolonged-release Apr-OM treat-
ments in an outpatient psychiatric setting. Main outcomes 
were reduction in relapses (psychiatric hospitalizations and 
urgent consultations) in the same patient when comparing 
the 6 and 12 months before and after the LAI implementa-
tion (mirror analysis), comparison of the three LAI-APDs’ 
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effectiveness in reducing relapses (urgent consultations and 
psychiatric hospitalizations) in the 6- and 12-month treat-
ments, and clinical and functioning improvement assessed 
after 6 and 12 months of treatment with the three LAI-APDs. 
Secondary observations were side effects reported during 
each LAI treatment and patient dropout (percentage and 
motivations).
Methods
ethical considerations
This retrospective observational study was conducted in 
2017 in the outpatient services of the Mental Health Depart-
ment of a northern Italian town according to general ethical 
procedures (Declaration of Helsinki). The present study 
was approved by the Area Vasta Emilia Nord Ethics Com-
mittee (protocol 3,181, August 28, 2017) and authorized by 
the Health Director of the Local Health Authority (decision 
1,780, October 2, 2017).
study participants
In the specific Italian context, after the 180 Law of 1978 
that closed asylums, the Mental Health Service was estab-
lished to provide community-based care, psychological and 
pharmacological treatments, and rehabilitative programs to 
patients affected by psychiatric disorders and their families. 
In the outpatient setting of the Mental Health Service, we 
retrospectively collected data from all patients affected 
by schizophrenia or other psychoses in the schizophrenic 
spectrum according to ICD9-CM classification68 (n=217) 
treated for the first time with Hal-D, PP-OM, or Apr-OM 
during the period from January 1, 2012 to October 31, 
2016. We decided to include all psychotic disorders of 
the schizophrenia spectrum in our participants, in order to 
evaluate the clinical efficacy of LAI-APDs in the most rep-
resentative sample of a real-world clinical setting. Patients 
who had started long-acting treatment after switching from 
either oral or other long-acting APD therapies were included. 
The concomitant use of other oral APDs did not constitute 
an exclusion criterion. All patients gave informed consent 
before LAI-treatment implementation.
For each patient, we collected the demographic variables 
age, sex, nationality, marital status, employment, living 
environment, and economic conditions; clinical variables of 
psychiatric diagnosis, substance abuse (including alcohol) 
in comorbidity, organic comorbidities, years of psychiatric 
illness, and number of previous psychiatric hospitalizations; 
pharmacological variables of reason for and modality of LAI 
prescription, posology, interval between administrations and 
number of LAIs per year, oral psychiatric drugs associated 
with LAIs at the beginning of treatment (T0), at 6 months 
(T6), and at 12 months (T12), and side effects and period 
of occurrence during LAI treatment; inpatient and outpa-
tient treatment variables of number of urgent consulta-
tions required during the 6–12 months before and after 
the introduction of LAI therapies, number and duration of 
psychiatric hospitalizations in the 6–12 months before and 
after the introduction of LAI therapies, and dropout from 
LAI treatments; clinical and functioning-scale variables of 
Clinical Global Impression – Severity (CGI-S) score69 at T0, 
CGI – Improvement (CGI-I)69 at T6 and T12, and Global 
Assessment of Functioning (GAF)70 at T0, T6, and T12.
research sources
Sociodemographic, clinical and pharmacological data of 
patients were collected from medical electronic charts of 
each patient. An interview with the patient’s psychiatrist 
was performed for clinical and functioning-scale evaluation.
Medication-treatment arms
The sample was divided into three groups based on the 
LAI-APD administered: PP-OM (n=114), Hal-D (n=55), 
and Apr-OM (n=48). Demographic, clinical, and pharmaco-
logical variables of the three groups were compared to one 
another to evaluate the homogeneity of the samples.
study assessments
End points analyzed were relapses (psychiatric hospitaliza-
tions and urgent consultations) 6 and 12 months before and 
after the introduction of LAI-APDs in the same patient, 
according to mirror-analysis design; comparison of relapses 
(psychiatric hospitalizations and urgent consultations) in the 
6 and 12 months before and after the LAI introduction in 
the three groups of patients; clinical improvement at 6 and 
12 months assessed through the CGI and GAF scales69,70 in 
the three groups; tolerability of LAI therapies in the three 
groups, through the evaluation of number, kind, and period 
of occurrence of side effects; dropout in the three groups; 
and correlations among variables selected and LAI-treatment 
duration or relapses (psychiatric hospitalizations and urgent 
consultations) at T12 in the three LAI groups.
statistical methods
Descriptive statistical tests performed were mean ± SD and 
t-tests for continuous variables and percentages, percentiles, 
and χ2 for categorical variables. The stepwise (backward 
selection) multiple linear regression model was used to 
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Table 1 sociodemographic and clinical characteristics of our sample
Characteristics PP-OM (n=114) Hal-D (n=55) Apr-OM (n=48) Total (n=217) Test: probability
sex, n (%)
Male 67 (58.8%) 32 (58.2%) 25 (52%) 124 (57.1%) χ2: Ns
Female 47 (41.2%) 23 (41.8%) 23 (48%) 93 (42.9%)
Nationality, n (%)
italian 92 (80.7%) 38 (69.1%) 41 (85.4%) 171 (78.8%) χ2: Ns
european 9 (7.9%) 4 (7.3%) 0 13 (6%)
Not european 13 (11.4%) 13 (23.6%) 7 (14.6%) 33 (15.2%)
age, mean ± sD
Years 42.7±14.3 46.3±12.5 41.4±10.8 43.32±13.23 t-test: Ns
employment status, n (%)
Unemployed 43 (37.72%) 24 (43.64%) 22 (45.83%) 89 (41%) χ2: Ns
employed 27 (23.68%) 8 (14.55%) 10 (20.83%) 45 (20.74%)
retired (age) 15 (13.16%) 8 (14.55%) 6 (12.5%) 29 (13.36%)
retired (disability) 26 (22.9%) 15 (27.26%) 10 (20.84%) 51 (23.52%)
student 3 (2.63%) 0 0 3 (1.38%)
living environment, n (%)
Parental family 59 (51.75%) 22 (40%) 20 (41.7%) 101 (46.54%) χ2: Ns
alone 13 (11.4%) 12 (21.8%) 7 (14.6%) 32 (14.77%)
Marital family 30 (26.32%) 17 (30.9%) 16 (33.4%) 63 (29.03%)
Protected facilities 9 (7.9%) 3 (5.5%) 4 (8.3%) 16 (7.36%)
homeless 3 (2.63%) 1 (1.8%) 1 (2%) 5 (2.3%)
socioeconomic condition, n (%)
Insufficient 35 (30.7%) 38 (69.1%) 25 (52%) 98 (45.16%) Pearson’s χ2=24.96: 
P,0.001Sufficient 79 (69.3%) 17 (30.9%) 23 (48%) 119 (54.84%)
(Continued)
analyze the correlations between our selected variables 
(independent variables) with dependent variables of duration 
of LAI treatment, number of relapses, number of urgent con-
sultations, and number of psychiatric hospitalizations. The 
duration of therapy was evaluated with the Kaplan–Meier 
survival curve. Statistical analysis was performed using 
Stata version 12.
Results
sociodemographic and clinical 
characteristics of sample
The sample was homogeneous for sex, age, and national-
ity, as well as living and employment conditions (Table 1). 
The three LAI-treatment groups did not differ significantly 
in sociodemographic characteristics, with the exception of 
the presence of socioeconomic problems, documented by 
the need for social service support, which was significantly 
higher in the Hal-D group (Table 1). Psychiatric diagnoses 
presented statistically significant differences among the three 
groups: paranoid schizophrenia was the most frequent in the 
PP-OM group, schizoaffective disorder was most prevalent 
among the Apr-OM group, whereas paranoid schizophrenia 
and delusional disorders were the most frequent disorders 
among patients treated with Hal-D (Table 1). The sample was 
homogeneous for the presence of organic comorbidities and 
substance abuse, including alcohol, as well as for years of 
illness and number of previous psychiatric hospitalizations 
(Table 1).
Pharmacological variables of the three 
lai treatments
Among the clinical motivations for LAI-treatment implemen-
tation, lack of therapeutic adherence was the main indication 
for the three LAI-APDs, while patient request was present 
only in the group treated with PP-OM and intolerance to 
previous therapies prevalent in the group treated with Apr-
OM (Table 2). The majority of patients treated with Hal-D 
and Apr-OM had previously taken oral APDs, whereas the 
group treated with PP-OM had mostly been treated with 
risperidone prolonged release or Hal-D (Table 2).
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Table 1 (Continued)
Characteristics PP-OM (n=114) Hal-D (n=55) Apr-OM (n=48) Total (n=217) Test: probability
Psychiatric diagnosis (icD9-cM), n (%)
Paranoid schizophrenia 46 (40.35%) 12 (21.83%) 8 (16.67%) 66 (30.41%) Pearson’s χ2=32.78: 
P,0.01Disorganized schizophrenia 4 (3.5%) 0 0 4 (1.84%)
Undifferentiated schizophrenia 13 (11.4%) 5 (9.09%) 0 18 (8.29%)
schizoaffective disorder 14 (12.28%) 10 (18.18%) 17 (35.41%) 41 (18.91%)
simple type schizophrenia 7 (6.14%) 5 (9.09%) 2 (4.17%) 14 (6.45%)
schizophreniform disorder 7 (6.14%) 6 (10.9%) 6 (12.5%) 19 (8.75%)
Delusional disorder 11 (9.65%) 10 (18.18%) 7 (14.58%) 28 (12.91%)
Other types of schizophrenia 12 (10.53%) 7 (12.73%) 8 (16.67%) 27 (12.44%)
substance and/or alcohol abuse, n (%)
absent 88 (77.2%) 41 (74.5%) 31 (64.58%) 160 (73.73%) χ2: Ns
Present 26 (22.8%) 14 (25.5%) 17 (35.42%) 57 (26.27%)
Organic comorbidity, n (%)
absent 73 (64%) 30 (54.5%) 35 (72.9%) 138 (63.6%) χ2: Ns
Present 41 (36%) 25 (45.5%) 13 (27.1%) 79 (36.4%)
Previous psychiatric hospitalizations, n (%)
0–3 80 (70.17%) 36 (65.45%) 28 (58.33%) 144 (66.37%) χ2: Ns
4–10 25 (21.93%) 14 (25.45%) 15 (31.25%) 54 (24.88%)
.10 9 (7.9%) 5 (9.1%) 5 (10.42%) 19 (8.75%)
Period of illness, mean ± sD
Years 11.70±8.19 14.35±9.39 11.13±6.80 12.24±8.29 aNOVa t-test: Ns
Abbreviations: Apr, aripiprazole; Hal-D, haloperidol decanoate; NS, not significant; OM, once monthly; PP, paliperidone palmitate.
Table 2 Modality of lai-aPD implementation in our sample
Pharmacological variables PP-OM (n=114) Hal-D (n=55) Apr-OM (n=48) Total (n=217) Test: probability
clinical motivation, n (%)
Inefficacy of previous therapies 23 (20.17%) 11 (20%) 5 (10.42%) 39 (17.97%) Pearson’s χ2=43.28: 
P,0.001intolerance of previous therapies 14 (12.28%) 7 (12.73%) 16 (33.33%) 37 (17.06%)
lack of therapeutic adherence 48 (42.1%) 37 (67.27%) 27 (56.25%) 112 (51.61%)
Patient choice 29 (25.45%) 0 0 29 (13.46%)
switch from oral or lai therapies, n (%)
From lai-aPDs 71 (62.28%) 18 (32.73%) 16 (33.33%) 105 (48.39%) Pearson’s χ2=18.57: 
P=0.001From oral antipsychotics 43 (37.72%) 37 (67.27%) 32 (66.67%) 112 (51.61%)
Previous antipsychotic drugs, n (%)
risperidone lai 50 (43.87%) 5 (9.09%) 3 (6.25%) 58 (26.73%) Pearson’s χ2=92.98: 
P,0.001hal-D 17 (14.91%) 0 3 (6.25%) 21 (9.68%)
Fluphenazine decanoate 4 (3.5%) 6 (10.9%) 3 (6.25%) 12 (5.53%)
Other oral antipsychotics 43 (37.72%) 37 (67.27%) 32 (66.67%) 112 (51.61%)
PP 0 6 (10.9%) 7 (14.58%) 13 (5.99%)
apr-OM 0 1 (1.82%) 0 1 (0.46%)
Abbreviations: aPD, antipsychotic drug; apr, aripiprazole; hal-D, haloperidol decanoate; lai, long-acting injectable; OM, once monthly; PP, paliperidone palmitate.
The mean OM posology of the three LAIs was 95.19 mg 
(25–150 mg) for PP-OM, 96.91 mg (25–188.4 mg) for 
Hal-D, and 394.93 mg (325–400 mg) for Apr-OM. We found 
that Apr-OM was prescribed at the maximum posology 
according to the official guidelines, whereas the other two 
LAI-APDs were prescribed at lower posology when 
compared with official indications: PP-OM at a dose lower 
than the 50th percentile (97.3 mg) and Hal-D at a dose 
between the 50th (88.6 mg) and 75th (150 mg) percentiles of 
official guideline indications. The interval in days between 
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each administration was similar in the three LAI groups: 
27.79 for PP-OM, 26.17 for Hal-D, and 28.55 for Apr-OM. 
The number of LAI administrations during the observation 
period was about one per month: 11.47 for PP-OM, 11.1 for 
Apr-OM, and 13.64 for Hal-D.
At the beginning of treatment (T0), 78% of patients of all 
three LAI groups were treated with associated oral psychiatric 
therapy. This percentage reduced to 68% after 6 months of 
treatment (T6), remaining stable after 12 months (T12). For 
each of the three LAI treatments, the number of associated 
psychiatric drugs significantly reduced both at T6 (t=3.76, 
P,0.01) and T12 (t=3.24; P=0.0014) in comparison to T0, 
without a statistically significant difference between T6 and 
T12. In patients treated with PP-OM and Hal-D, the prescrip-
tion of mood stabilizers increased at T6, remaining similar 
up to T12. In patients treated with Apr-OM, the prescription 
of antidepressant drugs increased at T6, remaining similar up 
to T12. Prescription of anticholinergics increased at T6 in the 
group treated with Hal-D, decreasing at T12. The concomi-
tant oral intake of FGA and SGA was very frequent in all 
three LAI groups during the year of observation, although it 
decreased at T12: 34% (n=39) at T6 and 30% at T12 (n=35) 
in the PP-OM group, 56% (n=31) at T6 and 47% (n=26) at 
T12 in the Hal-D group, and 23% (n=11) at T6 and 25% 
(n=12) at T12 in the Apr-OM group.
Mirror analysis and comparison of the 
three lai-aPDs
The mirror analysis showed a statistically significant reduction 
in both psychiatric hospitalizations and urgent consultations 
after 6 and 12 months of treatment with PP-OM (Figure 1), 
Hal-D (Figure 2), and Apr-OM (Figure 3) in comparison with 
the specular period before LAI implementation. In addition, 
hospitalization days in the same patient 12 months before 
and after the introduction of LAIs statistically significantly 
reduced in each of the three LAI groups (Figure 4).
Comparing the three LAI groups, we did not find any 
statistically significant difference (ANOVA) in the number 
of psychiatric hospitalizations and urgent consultations per-
formed during the 6 and 12 months after the introduction of 
LAIs. Similarly, hospitalization days during the 12 months 
after the introduction of LAI did not significantly differ 
among the three LAI groups (ANOVA).
side effects and dropout
Side effects affected 31% of subjects in the PP-OM group 
(35 patients), 25% in the Hal-D group (14 patients), and 
33% in the Apr-OM group (16 patients). There were no 



PRQWKV PRQWKV PRQWKV PRQWKV%HIRUH3320 $IWHU3320

 1XPEHUR
IUHODSVHVIRUSD
WLHQW 8UJHQWFRQVXOWDWLRQV3V\FKLDWULFKRVSLWDOL]DWLRQV
Figure 1 relapses (urgent consultations and psychiatric hospitalizations) in patients 
treated with PP-OM: mirror analysis at months 6 and 12.
Notes: *Versus urgent consultations in 6 months before PP-OM (t=3.74, P,0.001); 
**vs urgent consultations in 12 months before PP-OM (t=5.17, P,0.001); §vs 
psychiatric hospitalizations in 6 months before PP-OM (t=4.35, P,0.001); §§vs 
psychiatric hospitalizations in 12 months before PP-OM (t=4.09, P,0.001).
Abbreviations: OM, once monthly; PP, paliperidone palmitate.



PRQWKV PRQWKV PRQWKV PRQWKV%HIRUH+DO' $IWHU+DO'

 1XPEHUR
IUHODSVHVIRUSD
WLHQW 8UJHQWFRQVXOWDWLRQV3V\FKLDWULFKRVSLWDOL]DWLRQV
Figure 2 relapses (psychiatric hospitalizations and urgent consultations) in patients 
treated with hal-D: mirror analysis at months 6 and 12.
Notes: *Versus urgent consultations in 6 months before hal-D (t=3.94, P,0.001); 
**vs urgent consultations in 12 months before hal-D (t=4.8, P,0.001); §vs psychiatric 
hospitalizations in 6 months before hal-D (t=5.4, P,0.001); §§vs psychiatric 
hospitalizations in 12 months before hal-D (t=6.02, P,0.001).
Abbreviation: hal-D, haloperidol decanoate.
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



PRQWKV PRQWKV PRQWKV PRQWKV%HIRUH$SU20 $IWHU$SU20
8UJHQWFRQVXOWDWLRQV3V\FKLDWULFKRVSLWDOL]DWLRQV


1XPEHURIUH
ODSVHVIRUSDWLHQ
W
Figure 3 relapses (psychiatric hospitalizations and urgent consultations) in patients 
treated with apr-OM: mirror analysis at months 6 and 12.
Notes: *Versus urgent consultations in 6 months before apr-OM (t=4.96, P,0.001); 
**vs urgent consultations in 12 months before apr-OM (t=4.27, P,0.001); §vs 
psychiatric hospitalizations in 6 months before apr-OM (t=5.99, P,0.001) §§vs 
psychiatric hospitalizations in 12 months before apr-OM (t=4.05, P,0.001).
Abbreviations: apr, aripiprazole; OM, once monthly.
Figure 4 hospitalization days before and after lai implementation: mirror analysis 
at month 12.
Notes: *Versus hospitalization days in 12 months before PP-OM (t=3.02, P=0.001); 
**vs hospitalization days in 12 months before hal-D (t=4.09, P,0.001); ***vs 
hospitalization days in 12 months before apr-OM (t=3.87, P,0.001).
Abbreviations: apr, aripiprazole; hal-D, haloperidol decanoate; lai, long-acting 
injectable; OM, once monthly; PP, paliperidone palmitate.




3320 +DO' $SU20+RVSLWDOL]DWLRQGD\VEHIRUH/$,+RVSLWDOL]DWLRQGD\VDIWHU/$,
  1XPEHURIKRVS
LWDOL]DWLRQGD\V
IRUSDWLHQW
statistically significant differences in the occurrence of side 
effects among the three groups (t-test, ANOVA). All the LAI 
groups were similar for the period of side-effect occurrence, 
which presented after four to five injections on average for 
all three LAIs. Regarding the kind of side effects, although 
neurological disorders were prevalent in the Hal-D group, 
they frequently occurred even in patients taking the other 
two LAIs. In our sample, treatment with Hal-D did not cause 
cardiovascular, endocrine, or metabolic disorders, which 
appeared much more frequently in patients treated with 
PP-OM and Apr-OM.
The total percentage of dropout in the three LAI-therapy 
groups was 14.28% (31 patients), without any statistically 
significant differences among the three drugs, as shown in 
Table 3. We did not find any statistically significant differ-
ence among the three LAIs in number or period of relapses 
(psychiatric hospitalizations and urgent consultations, 
Table 3). The three LAI-APDs were also comparable to 
one another for the duration of treatment and reasons for 
discontinuation (Table 3), as shown in Figure 5, where the 
Kaplan–Meier curve shows evidences of an overlapping 
period of treatment in the three LAI groups.
cgi-s and cgi-i scales
Scores on the CGI-S scale at T0 differed significantly among 
the three LAI groups (Table 4). In particular, patients treated 
with PP-OM had lower CGI-S scores on average compared 
with the other two groups. There were no statistically sig-
nificant differences between CGI-I scores at T6 and T12 in 
any of the three LAI treatments (Table 4).
Analyzing CGI-S scores at T0 and CGI-I at T6 and T12, 
we found a statistically significant difference at T6 and T12 
compared to T0 and between T6 and T12 in all three LAI 
groups (Figure 6). In the PP-OM group, CGI-S scores at T0 
significantly differed in comparison with CGI-I scores at T6 
(t=16, P,0.001) and T12 (t=18.82, P,0.001) and CGI-I 
scores at T6 in comparison with T12 (t=5.7, P,0.001). In the 
Hal-D group, CGI-S scores presented a statistically signifi-
cant difference at T0 in comparison with CGI-I scores at T6 
(t=18.3, P,0.001) and T12 (t=24.04, P,0.001) and CGI-I 
scores at T6 in comparison with T12 (t=7.15, P,0.001). In 
the Apr-OM group, CGI-S scores at T0 significantly differed 
in comparison with T6 (t=14.82, P,0.001) and T12 (t=16.54, 
P,0.001) and CGI-I scores at T6 in comparison with T12 
(t=3.77, P,0.001).
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Table 3 lai-treatment period, dropout, and relapse
Pharmacological variables PP-OM (n=114) Hal-D (n=55) Apr-OM (n=48) Total (n=217) Test: probability
Period of lai treatment, mean ± sD
Days 332.50±87.06 345.82±57.01 335.79±72.52 336±77.16 t-test: Ns
Dropouts, n (%)
Patients in treatment 98 (86%) 48 (87.27%) 40 (83.33%) 186 (85.72%) χ2: Ns
Dropouts 16 (14%) 7 (12.73%) 8 (16.67%) 31 (14.28%)
reasons for lai dropout, n (%)
lack of therapeutic adherence 5 (4.38%) 2 (3.64%) 2 (4.17%) 9 (4.15%) χ2: Ns
Inefficacy 7 (6.12%) 4 (7.3%) 4 (8.33%) 15 (6.91%)
adverse effects 4 (3.5%) 1 (1.8%) 2 (4.17%) 7 (3.22%)
relapses, n (%)
No relapses 72 (63.18%) 31 (56.36%) 26 (54.17%) 129 (59.45%) χ2: Ns
Urgent consultations 34 (29.82%) 19 (35.54%) 18 (37.5%) 71 (32.72%)
Psychiatric hospitalizations 8 (7%) 5 (9.1%) 4 (8.33%) 17 (7.83%)
Abbreviations: Apr, aripiprazole; Hal-D, haloperidol decanoate; LAI, long-acting injectable; NS, not significant; OM, once monthly; PP, paliperidone palmitate.
Figure 5 Kaplan–Meier curve of treatment period in the three lai groups.
Abbreviations: apr, aripiprazole; hal-D, haloperidol decanoate; lai, long-acting injectable; OM, once monthly; PP, paliperidone palmitate.


    $QDO\VLVWLPHGD\V3320 +DO'$SU20
.DSODQ±0HLHUVXUYLYDOHVWLPDWHV
VXUYLYDO

At T0, the majority of patients were considered moder-
ately ill or notably sick on the CGI-S, while at T6 and T12 
the same subjects were considered mostly mildly improved 
or much improved. Patients discontinuing LAI treatment 
before the end of the observation period in all three groups 
did not have any statistically different CGI-S scores from 
those who continued treatment (t-test).
gaF scale
GAF scores differed significantly in the three LAI groups 
at T0, T6, and T12, as shown in Table 4. At all three time 
evaluations, the group of patients treated with Hal-D had the 
lowest value, subjects treated with PP-OM had the highest 
scores and thus better overall functioning, whereas treated 
those with Apr-OM presented intermediate scores compared 
to the other two groups. GAF scores were statistically sig-
nificant different at T6 and T12 compared to T0 and between 
T6 and T12 in all three LAI groups (Figure 7). Analysis of 
GAF scores revealed a statistically significant difference at 
T6 (t=-6.06, P,0.001) and T12 (t=-8.56, P,0.001) com-
pared to T0 and between T6 and T12 (t=-6.47, P,0.001) 
in the PP-OM group. In the Hal-D group, GAF scores at T0 
showed a statistically significant difference from T6 (t=-7.43, 
P,0.001) and T12 (t=-8.76, P,0.001) and between T6 and 
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Table 4 cgi and gaF scores at T0, T6, and T12
Clinical and 
functioning scales
PP-OM (n=114) Hal-D (n=55) Apr-OM (n=48) Total (n=217) Test: probability
cgi, mean ± sD
cgi-s T0 4.96±0.95 5.49±0.74 5.56±0.77 5.52±0.9 aNOVa F=11.74: P,0.001
cgi-i T6 3.41±0.77 3.67±0.61 3.38±0.61 3.47±0.70 aNOVa t-test: Ns
cgi-i T12 2.95±0.84 3.02±0.38 2.9±0.49 2.96±0.68 aNOVa t-test: Ns
gaF, mean ± sD
gaF T0 41.80±11.86 36.27±7.15 40.94±9.03 40.21±10.47 aNOVa F=5.56: P,0.001
gaF T6 49.36±14.86 40.28±9.24 45.80±9.69 46.18±13.03 aNOVa F=9.42: P,0.01
gaF T12 52.67±14.10 42.81±10.31 49.25±9.64 49.39±12.96 aNOVa F=10.21: P,0.001
Abbreviations: apr, aripiprazole; cgi-i, clinical global impression – improvement; cgi-s, clinical global impression – severity; gaF, global assessment of Functioning; 
Hal-D, haloperidol decanoate; NS, not significant; OM, once monthly; PP, paliperidone palmitate; T0, baseline; T6, 6 months; T12, 12 months.



&*,67 &*,,7 &*,,7
3320+DO'$SU20
&*,6DQG&*,,
VFRUHV
Figure 6 cgi-s and cgi-i scores (±sD) at T0, T6, and T12 in the three lai groups.
Abbreviations: apr, aripiprazole; cgi-i, clinical global impression – improvement; 
cgi-s, cgi – severity; hal-D, haloperidol decanoate; lai, long-acting injectable; OM, 
once monthly; PP, paliperidone palmitate; T0, baseline; T6, 6 months; T12, 12 months.



*$)7 *$)7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7
3320+DO'$SU20
*$)VFRUHV
Figure 7 gaF scores (±sD) at T0, T6, and T12 in the three lai groups.
Abbreviations: apr, aripiprazole; gaF, global assessment of Functioning; 
hal-D, haloperidol decanoate; lai, long-acting injectable; OM, once monthly; 
PP, paliperidone palmitate; T0, baseline; T6, 6 months; T12, 12 months.
T12 (t=-5.09, P,0.001). In the Apr-OM group, GAF scores 
differed significantly at T6 (t=-10.76, P,0.001) and T12 
(t=-13.33, P,0.001) compared to T0 and between T6 and 
T12 (t=-5.55, P,0.001).
Patients discontinuing treatment before the end of the 
observation period in all three groups did not have any 
statistically significant difference in GAF scores from those 
who continued treatment (unpaired t-test).
Factors associated with relapses 
(psychiatric hospitalizations and urgent 
consultations)
In our multiple linear regression model, the number of hos-
pitalizations at 12 months was significantly positively cor-
related with CGI-S scores at T0 (correlation coefficient 0.12, 
SE 0.04, 95% CI 0.04–0.2; P=0.002) and with the variable 
“retired for disability” (correlation coefficient 0.31, SE 0.09, 
95% CI 0.14–0.5; P,0.001) in all three LAI groups. 
Similarly, we observed a statistically significant positive 
correlation between the number of urgent consultations at 
12 months and the CGI-S score at T0 (correlation coefficient 
0.67, SE 0.18, 95% CI 0.32–1.03; P,0.001) and the variable 
“retired for disability” (correlation coefficient 1.1, SE 0.34, 
95% CI 0.43–1.78; P=0.001) in all three LAI groups.
Factors associated with duration of lai 
treatment
In our multiple linear regression model, the duration of 
treatment in days was positively correlated with CGI-S 
scores at T0 (correlation coefficient 15.9, SE 6.52, 95% 
CI 3.05–28.76; P=0.016) and negatively with side-effect 
occurrence (correlation coefficient -24.72, SE 11.05, 95% 
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CI -46.51 to -2.93; P=0.026) in a statistically significant 
way in all three LAI groups.
Discussion
The present study analyzed the effectiveness of 6- and 
12-month treatment with one of three LAIs (PP, Hal-D, 
prolonged-release Apr) in a group of patients affected by 
schizophrenia and other psychoses of the schizophrenic 
spectrum treated in an outpatient psychiatric service.
sociodemographic and clinical 
characteristics of sample
Our sample of 217 patients presented a margin of error of 
6.62% (at 95% CI), whereas with a margin of error of 5% 
the sample should have consisted of 377 patients. The sample 
size, albeit limited, was similar to that of several other natural-
istic studies on the effectiveness of LAI-APDs in a naturalistic 
setting.57,59,60 The sample can be considered representative of 
the population of a mental health outpatient service, due to the 
broad criteria of inclusion. Our patients were mostly Italians 
with a long clinical history (10 years of illness on average and 
numerous previous psychiatric hospitalizations) and with dif-
ficult sociorelational adjustment conditions. In fact, most lived 
with their parental family, did not work, and needed economic 
support from the local social service. These data confirmed the 
observation of another recent study, which highlighted that 
LAI treatments were more frequently prescribed to subjects 
with low income and/or socioeconomic problems.71
Our patients presented high clinical severity, as shown 
by CGI-S scores at T0, indicating that the majority of them 
were scored between notably sick (CGI-S 5) and severely ill 
(CGI-S 6). These data are not in line with other LAI studies, 
which included patients with less severe disorders,59,72–74 but 
confirms that LAI-APDs are mostly administered to patients 
with severe disorders after several years of illness and numer-
ous therapeutic failures.11,76,77
We found that patients treated with PP-OM had signifi-
cantly lower scores on the CGI-S scale at T0 compared to 
others, probably because most patients of this group switched 
from risperidone prolonged release to PP-OM with the moti-
vation of reducing both costs and number of administrations, 
but not for the worsening of psychosis, as in other studies.65,66 
In comparison to other studies, which showed a more frequent 
prescription of LAI-APDs in subjects with substance abuse,78 
our sample did not show relevant organic comorbidities or 
substance abuse, including alcohol.
The three LAI groups were statistically comparable in 
their sociodemographic and clinical characteristics, which 
differed significantly from each other for only two vari-
ables: need for economic support from social service and 
type of schizophrenia. Specifically, 60% of patients treated 
with Hal-D needed support from social services, congruent 
with low GAF scores reported by these patients, showing 
reduced functioning abilities. Schizoaffective disorder pre-
vailed among patients treated with Apr-OM, who were con-
comitantly prescribed oral antidepressants at a much higher 
percentage than the other two LAI groups. The tendency to 
prefer SGAs in patients affected by schizoaffective disorders 
has been highlighted by other studies carried out in different 
countries,58,59 where SGA LAIs are also approved for bipolar 
disorders.
Pharmacological treatment variables with 
the three lai antipsychotics
The observation period of 1 year is in line with most studies 
in the literature.24,26,79 Unlike other research,58–60,72,73,80 we 
selected all patients treated with one of the three LAI-APDs 
whose treatment started in the selected period of 5 years, 
regardless of previous APD treatments, in order to collect a 
sample as close as possible to a real-world clinical setting. 
Failure of adherence to previous prescriptions represented 
the main reason for choosing one of three LAI-APDs, in 
accordance with international guidelines.17–19,81 The average 
dosage of administration was different for the three LAIs. 
PP was prescribed at an average dose of ,100 mg monthly, 
in line with other studies,60,74,80 which however included 
patients with lower scores on the CGI-S scale and thus were 
clinically less severe. The dosage of Hal-D was widely vari-
able (25–300 mg/month), but ,100 mg/month on average, 
although according to the technical data sheet,31 it is possible 
to prescribe up to 300 mg monthly in cases of clinically severe 
illness. Therapy with Apr prolonged release was in line with 
the therapeutic indications,44 with a maximum dosage of 
400 mg per month in the entire sample, since only a few 
patients received injections of 300 mg per month. Our results 
show that the posology of paliperidone and Hal, unlike that 
of Apr, was flexible and lower than the maximum indicated 
by the official guidelines, despite the clinical severity of 
our patients. The more flexible doses of Hal-D and PP-OM 
reflect the indications of the drugs’ pharmaceutical company 
and official guidelines, but could have been conditioned by 
the tolerability profile of these drugs. We emphasize that the 
group of patients treated with PP-OM showed less severe con-
ditions at T0, so they could benefit from a low maintenance 
dosage. The other two groups showed greater clinical severity 
on scale scores. We also note that the relatively low posology 
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of Hal, despite the severity of patients at T0, could have been 
justified by the prudential attitude of therapists, probably due 
to the known cardiologic and neurological side effects of this 
molecule, despite some clinical studies32 indicating the dose 
of 200 mg OM as the most effective to prevent relapse. In 
response to the conservative prescription of LAI-APDs, wide 
use of oral APD therapy was observed in the whole sample, 
mainly at T0, which was significantly reduced at T6 and T12, 
with no statistically significant difference among the three 
groups. At the end of the observation period (T12), 30% of 
patients treated with PP, 45% of subjects with Hal-D, and 
25% with Apr prolonged release still took oral APD thera-
pies, in accordance with the percentages reported in other 
studies.72,73,82 In line with other studies,57 the group treated 
with the FGA LAI (Hal-D) presented the highest percentage 
of associated oral APD and anticholinergic drugs. This result 
confirms the risk of the well-known neurological side effects 
of this drug and further suggests that this group consisted of 
patients suffering from serious disorders. In subjects treated 
with PP-OM or Apr-OM, we found greater use of antidepres-
sants, mood stabilizers, and benzodiazepines, and at T12, 
lower use of APDs and anticholinergics. In particular, with 
Apr-OM, there was a similar frequency in the use of mood 
stabilizers, antidepressants, and benzodiazepines at T12, data 
that indirectly confirm the greater percentage of patients with 
schizoaffective disorder in this group.
Efficacy of antipsychotic LAI therapy: 
mirror analysis and comparison of the 
three lai-aPDs
With regard to the primary objective of this study, PP, Hal-D, 
and Apr prolonged release proved to be equally effective in 
the prevention of relapses both at 6 and 12 months, resulting 
in a significant decrease in urgent consultations, psychiatric 
hospitalizations, and days of hospitalization. Our study 
confirms results obtained from previous research conducted 
with mirror analysis23,26,73–75 or cohort-study design25,30 that 
demonstrated greater efficacy of LAI-APDs compared to 
oral APD therapies in the prevention of relapses. These 
results were not confirmed by the double-blind RCTs,6 prob-
ably because RCTs are not an optimal study methodology 
for effectiveness studies in clinical practice.29 Our study, 
unlike others,6,74,83,84 also compared in mirror design urgent 
psychiatric consultations at 6 and 12 months of LAI treat-
ments. Urgent consultations can represent a more sensitive 
and specific indicator of relapse, since the occurrence of 
hospitalizations and their duration can be influenced by 
organizational and contextual factors, such as availability 
of beds in hospital wards and the therapist’s attitude toward 
hospitalization treatments.
Although our patients had a long history of disorder and 
high clinical severity, only 7.83% (n=17) of the whole sample 
was hospitalized during the year following the introduction 
of LAI drugs, and more than half did not present any type 
of relapse. This result indicates that all three LAI therapies 
can be valid therapeutic options to prevent recurrences in 
schizophrenic psychosis, confirming what emerged from 
studies conducted in real-world clinical practice.6,30,74,79,80 
All three LAI-APDs similarly induced significant improve-
ment in CGI-I and GAF scale scores at T6 and T12. 
This result further confirms their efficacy in improving 
both psychotic symptoms and functional impairments in 
schizophrenia. In our work, SGA did not differ from Hal-D 
in relapse prevention, in line with other studies on LAI 
comparison.56–58,83,85 The only factor associated with a greater 
number of relapses at 12 months in all three LAI groups was 
high CGI-S score at T0, an indicator of clinical severity at 
the beginning of LAI treatment, as well as being “retired 
for disability”, a condition secondary to the negative impact 
of schizophrenia on working ability and social adaptation.
The duration of treatment and reasons for interruption did 
not differ significantly among the three LAI groups. Only a 
very small percentage of patients abandoned the LAI therapy, 
on average about 14% (n=31) of the total sample. There were 
no differences in frequeny of dropout among the three LAIs, 
unlike what emerged from other studies84 in which FGA LAIs 
were interrupted with higher frequency and were continued 
for only 1 year by 10% of patients. In our sample, the rate of 
discontinuation of LAI-APD was similar to that found in a 
Canadian study of PP,80 but was different from other studies. 
In a study carried out in Belgium and the Netherlands, the 
12-month continuation rate of LAI therapy in an outpatient 
setting was ,50% for a wide range of drugs (Hal-D, pro-
longed-release risperidone, olanzapine pamoate, PP).64 In the 
UK, researchers have estimated a continuation rate of 60% in 
1-year PP treatment.86 Cordiner et al59 found 52% interruption 
in 18-month therapy with PP, 38% for zuclopenthixol, and 
28% for risperidone prolonged release. These differences 
can also be explained by the way in which mental health 
services are organized. In particular, the working modality of 
a psychiatric service, which provides a monitoring system 
of LAI therapy, such as calling subjects for LAI treatment 
in cases of nonpresentation, could promote therapeutic con-
tinuity, improving patient treatment adherence. Our study 
found that the severity of disorder (as shown by CGI-S score 
at T0) was correlated with longer duration of LAI therapy, 
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indicating that patients with the most serious disorders were 
more assiduously monitored by our outpatient psychiatric 
service in order to avoid therapy discontinuation. All data 
related to LAI therapy, including our results, highlighted 
much higher therapeutic continuity than reported with oral 
APDs, whose percentage of 18-month therapy interruption 
was 74% for both FGAs and SGAs according to a review.8
side effects
The number of side effects and period of their occurrence 
were similar in the three LAI groups, although there were 
differences regarding the type of adverse events. Only 
seven patients in the entire sample (3.22%) interrupted LAI 
therapies due to side effects, without significant differences 
among the three groups. The presence of adverse events was 
the only factor that negatively correlated with the duration 
of LAI therapies, without any difference among the three 
LAI treatments.
In line with the literature, Hal-D presented mostly neu-
rological side effects,58 whereas PP caused mainly metabolic 
and endocrine adverse events.43,86 Unlike other research,50,51 
Apr prolonged release in our study induced metabolic 
and endocrine side effects, albeit at a lower rate than PP. 
We thus did not find therapeutic advantages in terms of 
tolerability between an FGA (Hal) and the other two SGAs 
(PP and Apr), since all three LAI groups had similar rates 
and severity of adverse events, although of different types, 
in accordance with previous studies.58 Nevertheless, it should 
also be noted that Apr prolonged release was prescribed 
at full dose, whereas PP and Hal-D were administered at 
intermediate dosages according to guideline indications, a 
condition that may have favorably affected the good toler-
ability to these two drugs.
In our study, the side effects occurred on average after 
five doses of LAI-APD, whereas in other studies they were 
already evident following the first injection,44,72,73 probably 
due to the prudential modality of prescription registered in 
this study. Therefore, in line with the literature data, our 
results suggest that even if there are differences in some 
specific clinical and functional domains, there is not currently 
any unambiguous demonstration of the superior efficacy of 
one LAI compared to another.8,67,81,87
limits and advantages of this study
The observational and retrospective design of this study did 
not allow us to collect data beyond those already present in 
patient medical records nor to establish causative inferences 
among the selected variables. No subjective questionnaires 
on quality of life or satisfaction with therapy were given to 
patients, as seen in other studies. No numerical data were 
systematically collected on metabolic side effects (eg, 
changes in the body-mass index, lipid and carbohydrate 
profile), or extrapyramidal symptoms (such as specific scale 
scores). Furthermore, the observation period was limited to 
1 year, whereas a longer period could have provided more 
information.
The present research included a large number of patients 
(n=217), enrolled in outpatient services of a Mental Health 
Department, which consists of urban and suburban contexts, 
offering a wide and comprehensive observation of a real-world 
clinical setting. Relapses were assessed not only in terms of 
number and duration of hospitalizations but also through 
a more sensitive indicator, such as urgent consultations. 
Our research combined an effectiveness evaluation through 
mirror analysis performed for each individual patient 
with subsequent comparison among the three LAI-APDs, 
allowing us a more complete evaluation of clinical efficacy.
Conclusion
PP, Hal-D, and prolonged-release Apr demonstrated similar 
effectiveness in preventing relapses and showed overlapping 
improvement of the clinical condition and functioning of 
patients at 6 and 12 months of treatment. Moreover, the toler-
ability profile of the three LAI-APDs was found to be similar 
in terms of number and severity of registered side effects, 
although of different typology: neurological for Hal-D and 
metabolic and endocrine for paliperidone and Apr. The 
effectiveness of all three treatments was also suggested by 
the low interruption rate, similar among the three groups for 
frequency and motivation. Our research, despite having iden-
tified a similar profile of efficacy and tolerability of the three 
long-acting APDs, showed different prescriptive modalities 
in the three LAI treatments, which could have affected their 
effectiveness: PP was prescribed at low–medium doses in 
patients with lower clinical severity, Hal-D was prescribed 
at medium doses in more severe and socially disadvantaged 
patients, and Apr was prescribed at full dosing to patients 
predominantly suffering from schizoaffective disorders. 
This research indicates that PP, Hal, and Apr in long-acting 
formulations constitute important therapeutic options in 
patients suffering from serious and long-term disorders, 
due to increased patient adherence to treatment, which 
reduces the need for urgent consultations and hospitaliza-
tions, improving the clinical course of schizophrenia. At the 
same time, LAI therapies permit mental health services to 
reduce the burden of both economic cost and overwhelming 
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workload. This observational survey reports the contradic-
tions and complexity of a real-world setting, as denoted by 
the prudential use of LAI-dose prescription and at the same 
time the high percentage of associated oral APDs. In light of 
our results, we can conclude that (as already indicated in the 
literature) there are currently no unequivocal indications of 
superior efficacy of one LAI-APD compared to another. In 
general, the attitude of psychiatrists toward the modality in 
which LAI therapy is prescribed and carried out can strongly 
influence the acceptance of these drugs by patients and the 
stigma associated with LAI therapy. Finally, we point out, 
as the main international guidelines state,16,81 that the best 
practice in prescribing an LAI-APD is to identify with the 
patient the therapy that best meets his/her needs, seeking their 
conscious and informed acceptance of long-term treatment. 
Therefore, to improve the acceptance of long-acting therapy, 
we reiterate the need to involve patients in the therapeutic 
process, even in situations where awareness of disorder is 
labile and therapeutic adherence poor, as pointed out by other 
authors.77 Further, longer-term prospective studies examining 
other LAI-APDs are needed, with more objective measures 
of side effects and subjective scales that assess the quality 
of life perceived by patients, to confirm the results obtained 
in the present research.
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